menu
    • menu
    [{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"Norgine","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Covis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Norgine","sponsor":"Fennec Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Norgine","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dantrolene","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Not Applicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Not Applicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Mavorixafor","moa":"CXCR4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Norgine","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.26000000000000001,"dosageForm":"Capsule","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Norgine"}]

    Find Clinical Drug Pipeline Developments & Deals by Norgine

    Menu

    Norgine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : $260.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            X4 Pharmaceuticals, Norgine Sign License for Mavorixafor in Europe, Australia

                            Details : Under the licensing agreement, Norgine will hold exclusive rights to commercialize Xolremdi (mavorixafor) in Europe, Australia, etc. It is being indicated for the treatment of WHIM syndrome.

                            Product Name : Xolremdi

                            Product Type : Other Small Molecule

                            Upfront Cash : $29.1 million

                            January 13, 2025

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : $260.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Norgine Submits DFMO Marketing Application to EMA for Neuroblastoma

                            Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                            Product Name : Iwilfin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Norgine Submits MAA for Eflornithine in High-Risk Neuroblastoma via Project Orbis

                            Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                            Product Name : Iwilfin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dantrolene

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Norgine Receives Positive ChMP Opinion for NPJ5008 for Treating Malignant Hyperthermia

                            Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.

                            Product Name : NPJ5008

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Dantrolene

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Thiosulfate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved

                            Recipient : Fennec Pharmaceuticals

                            Deal Size : $271.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fennec and Norgine License PEDMARQSI for Europe, Australia, New Zealand

                            Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.

                            Product Name : Pedmarqsi

                            Product Type : Small molecule

                            Upfront Cash : $43.4 million

                            March 18, 2024

                            Lead Product(s) : Sodium Thiosulfate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved

                            Recipient : Fennec Pharmaceuticals

                            Deal Size : $271.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Goldman Sachs Asset Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Norgine Announces Closing of Investment from Goldman Sachs Asset Management

                            Details : The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.

                            Product Name : Movicol

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Goldman Sachs Asset Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Recipient : Covis Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data in The European Heart Journal Show Ciraparantag Reverses the Anticoagulant Activity of Apixaban and R...

                            Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).

                            Product Name : PER977

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2021

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Recipient : Covis Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : US WorldMeds

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Norgine Enter Agreement to Commercialise DFMO in Independent States

                            Details : DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality thera...

                            Product Name : DFMO

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 23, 2021

                            Lead Product(s) : Eflornithine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : US WorldMeds

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Recipient : AMAG Pharmaceuticals

                            Deal Size : $290.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europ...

                            Details : Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontro...

                            Product Name : PER977

                            Product Type : Small molecule

                            Upfront Cash : $30.0 million

                            July 23, 2020

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Recipient : AMAG Pharmaceuticals

                            Deal Size : $290.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            NeuroForum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Faes Farma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU

                            Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Faes Farma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth